Finding Maximum Tolerated Dose in Phase I Oncology Clinical Trials with Bayesian Methods

被引：0
|
作者：
Sapi, Johanna [1 ,2 ]
机构：
[1] Obuda Univ, Biomat & Appl Artificial Intelligence Inst, John von Neumann Fac Informat, Becsi Ut 96-B, H-1034 Budapest, Hungary
[2] Obuda Univ, Univ Res & Innovat Ctr, Physiol Controls Res Ctr, Becsi Ut 96-B, H-1034 Budapest, Hungary
来源：
ACTA POLYTECHNICA HUNGARICA | 2024年 / 21卷 / 06期
关键词：
maximum tolerated dose (MTD); dose-limiting toxicity (DLT); Continual Reassessment Method (CRM); Time-To-Event Continual Reassessment Method (TITE- CRM); copula regression model; logistic regression model; delayed toxicities; late-onset toxicity model; CONTINUAL REASSESSMENT; DESIGN; TOXICITY; COMBINATIONS; AGENT;
D O I：
暂无
中图分类号：
T [工业技术];
学科分类号：
08 ;
摘要：
Maximum tolerated dose (MTD) is a maximal amount of drug or radiation resulting relatively acceptable dose-limiting toxicity (DLT). Accurate value of MTD should be found in Phase I trials in order to create the possibility to conduct successful Phase II (pilot efficacy and safety evaluation) and Phase III (comparative efficacy) trials. The aim of this paper is to review the difficulties of the dose-finding methods including multi-agent problems and late-onset toxicities, and to discuss Bayesian adaptive dose-finding methods which can handle these issues.
引用
收藏
页码：129 / 145
页数：17
相关论文
共 50 条
  • [1] Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials
    Takahashi, Ami
    Suzuki, Taiji
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 21
  • [2] A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs
    Li, Chen
    Sun, Hongying
    Cheng, Cheng
    Tang, Li
    Pan, Haitao
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2022, 30
  • [3] Application of Bayesian hierarchical models for phase I/II clinical trials in oncology
    Yada, Shinjo
    Hamada, Chikuma
    PHARMACEUTICAL STATISTICS, 2017, 16 (02) : 114 - 121
  • [4] Bayesian dose finding in phase I clinical trials based on a new statistical framework
    Ji, Y.
    Li, Y.
    Yin, G.
    STATISTICA SINICA, 2007, 17 (02) : 531 - 547
  • [5] A robust Bayesian dose-finding design for phase I/II clinical trials
    Liu, Suyu
    Johnson, Valen E.
    BIOSTATISTICS, 2016, 17 (02) : 249 - 263
  • [6] Innovations for phase I dose-finding designs in pediatric oncology clinical trials
    Doussau, Adelaide
    Geoerger, Birgit
    Jimenez, Irene
    Paoletti, Xavier
    CONTEMPORARY CLINICAL TRIALS, 2016, 47 : 217 - 227
  • [7] A Bayesian dose finding design for oncology clinical trials of combinational biological agents
    Cai, Chunyan
    Yuan, Ying
    Ji, Yuan
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2014, 63 (01) : 159 - 173
  • [8] An integrated dose-finding tool for phase I trials in oncology
    Yang, Shengjie
    Wang, Sue-Jane
    Ji, Yuan
    CONTEMPORARY CLINICAL TRIALS, 2015, 45 : 426 - 434
  • [9] Two-stage dose finding for cytostatic agents in phase I oncology trials
    Yin, Guosheng
    Zheng, Shurong
    Xu, Jiajing
    STATISTICS IN MEDICINE, 2013, 32 (04) : 644 - 660
  • [10] An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials
    Hirakawa, Akihiro
    STATISTICS IN MEDICINE, 2012, 31 (06) : 516 - 532
12345